Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

A method of treating an ocular inflammatory disease in a subject in need of such treatment, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist of Formula II:

• wherein:
• a is 1 and b is 0;
• a is 0 and b is 1, or a is 1 and b is 1;
• R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, -NR11 R12 or -OR13 ;
• R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
• R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11 R12, NO2 optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11 R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R5 is halogen, —CF3 or —S(O)n R14;
• n is 0, 1 or 2;
• R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11 R12, NO2 , optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R7is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11 R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
• R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
• R10is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
• R9a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
• R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
• R11 is hydrogen or optionally substituted C1-8 alkyl;
• R12 is hydrogen or optionally substituted C1-8 alkyl;
• R13 is hydrogen or optionally substituted C1-8 alkyl;
• R14 is hydrogen, CF3 or optionally substituted C1-8 alkyl;
• and R15 is hydrogen or optionally substituted C1-8 alkyl;
• wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD.